CRISPR/Cas9 was employed to edit four tumor suppressor (P53, PTEN, RB1, and NF1) genes in breast organoids, resulting into the development of ER-α luminal breast cancer [50], which indicated that the inactivation of these four tumor suppressor genes are key drivers in generating BC under in vivo condition. Here, ESR1 is linked to breast cancer.